© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
Experts in pulmonology provide insight on the diagnosis and optimal management of idiopathic pulmonary fibrosis (IPF).
November 11th 2021
Steven D. Nathan, MD, FCCP, provides an overview of idiopathic pulmonary fibrosis, including long-term disease complications and the effect on a patient’s quality of life.
December 21st 2021
Expert pulmonologists discuss the effect of early and late diagnosis on IPF disease management, as well as the importance of a multidisciplinary team approach to treatment.
Steven D. Nathan, MD, FCCP, leads the discussion on the differential diagnosis of idiopathic pulmonary fibrosis (IPF).
Drs Fernando J. Martinez and Steven D. Nathan review the goals of therapy and the importance of non-pharmacological therapies for the management of IPF.
Experts in pulmonology discuss the safety and efficacy of pirfenidone and nintedanib for the management of IPF.
Fernando J. Martinez, MD, MS, and Steven D. Nathan, MD, FCCP, share their personal experiences using pirfenidone and nintedanib in clinical practice and discuss the role of managing comorbidities for the treatment of IPF.
Expert pulmonologists comment on emerging therapies in the pipeline for the treatment of IPF.
Steven D. Nathan, MD, FCCP, and Fernando J. Martinez, MD, MS, share clinical pearls and advice for the management of IPF.
Glycemic Variability, High Glucose Increase Mortality Risk in Patients with Type 2 Diabetes
Daily Insulin Titration Results in Lower Fasting Glucose for Gestational Diabetes
Beti-Cel Gene Therapy for β-Thalassemia Receives FDA Approval